

NALCCON - 2018 PATNA
Sunday, 7th October (Day-2)

TIME/ROLE	TOPIC/Faculty
8:00 AM	REGISTRATIONS
09:00 AM - 09:40 AM	SESSION 7 : Early Stage (Resectable) NSCLC: Can we increase the percentage of patients who get surgery? (PRO-CON DEBATE:)
09:40 AM - 10:20 AM	SESSION 8 : Panel Discussion: First line treatment of EGFR mutated NSCLC & the role of sequencing: 1st vs. 2nd vs. 3rd generation TKIs
10:20 AM - 11:00 AM	SESSION 9 : Panel Discussion: First line treatment of ALK rearranged NSCLC & the role of sequencing: 1st vs. 2nd generation TKIs
11:00 AM - 11:20 AM	TEA - BREAK
11:20 AM - 12:00 PM	SESSION 10 : Panel Discussion: Integrating IO into first line treatment of metastatic NSCLC without oncogenic drivers – Challenges in the Indian context
12:00 PM - 12:40 PM	SESSION 11 : Panel Discussion: Emerging role of liquid biopsy and rebiopsy at progression in metastatic NSCLC
12:40 PM - 01:20 PM	SESSION 12 : Patient Advocacy for Lung Cancer in India: Need of the hour
01:20 PM - 02:00 PM	LUNCH - BREAK
02:00 PM - 03:00 PM	SESSION 13 : Young Investigator Award Session
03:00 PM - 03:40 PM	SESSION 14 : Current role of oral and parenteral VEGF inhibitors in management of treatment naïve and relapsed metastatic NSCLC
03:40 PM - 04:00 PM	TEA - BREAK
04:00 PM - 05:00 PM	SESSION 15 : Year in review: Advances in management of brain metastases
04:20 PM - 05:00 PM	Panel Discussion: Current role of WBRT in management of brain meets in era of targeted therapies and IO
05:00 PM - 05:10 PM	Concluding remarks, Feedback, Vote of Thanks